Sanchez, Lisa A.; Holdsworth, Mark; Bartel, Sylvia B. - In: PharmacoEconomics 18 (2000) 6, pp. 533-556
: ondansetron, granisetron and dolasetron. The most important treatment-related factor contributing to CIE is the emetogenicity of … ondansetron, but is not as favourable for granisetron or dolasetron. As the rationale and justification for dose stratification is …